trial

A Study to Assess the Efficacy and Safety of KarXT in Acutely Psychotic Hospitalized Chinese Adult Subjects With DSM-5 Schizophrenia

NCTId NCT05919823
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 3 · Completed
Enrollment 202 (actual)
Sponsored by Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Primary completion 2024-09-16
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 3
Status
Completed
Enrollment
202 (actual)
Study type
Interventional
Allocation
Randomized
Model
Factorial
Masking
Triple
Start
2023-05-29
Primary completion
2024-09-16
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
Xanomeline-trospium (Cobenfy)

Sponsors

Karuna Therapeutics, Inc., a Bristol Myers Squibb companyLead Sponsor
Zai Lab (Shanghai) Co., Ltd.Collaborator

Sites

28 total
Hefei, ChinaWuhu, ChinaBeijing, ChinaBeijing, ChinaChangping, ChinaChongqing, ChinaJiangbei, ChinaGuanzhou, ChinaBaoding, ChinaDaqing, ChinaZhumadian, ChinaWuhan, China

Linked catalysts

1
A Study to Assess the Efficacy and Safety of KarXT in Acutely Psychotic Hospital — primary completion2024-09-16

Facts & assertions

4 sourced
Enrollment
202
Phase
PHASE3
Primary Completion Date
2024-09-16
Status
COMPLETED
relationships
The graph out of here
drug
Xanomeline-trospium (Cobenfy)
drug
lead_sponsor
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
company
collaborator
Zai Lab (Shanghai) Co., Ltd.
company
indication
Schizophrenia
indication
Schizophrenia
indication